Featured news from NHIVNA
HIV-related news from NAM
Gay men’s PrEP study final results: near 90% efficacy in men who took drug, but adherence even lower than thought
Gus Cairns, 2011-07-22 10:50:00
A completed series of investigations into the iPrEx study of tenofovir/FTC(Truvada) at pre-exposure prophylaxis (PrEP) has found that the drug was 87% efficacious in preventing HIV infection amongst those who had detectable drug levels, though only 42% efficacious overall.
An expanded number of drug-level tests show that only 44% of those who did not become infected with HIV had drug detectable in their blood and/or cells, suggesting that overall adherence in the study was even lower than thought. This suggests that adherence will be the factor that may limit the effectiveness of this strategy in curbing HIV in many populations, and that it may need to be offered only to people highly motivated to take it.
Source:1
